Adrelia Allen
Adrelia is a 23-year veteran of the pharmaceutical industry working in sales and clinical research at Merck. She has held positions of increasing experience as a Clinical Research Associate, Clinical Trial Project Manager, and Clinical Research Manager. She is currently, the Senior Director of Clinical Trial Patient Diversity where she leads a team of clinical trial operations experts focused on promoting inclusive research practices to support the enrollment of diverse patients in Merck clinical trials. She is responsible for the execution and strategy implementation for clinical trial processes, resources, and training to help drive inclusion and access across our clinical trial portfolio. Due to her commitment and determination to drive greater representation in clinical trials, Adrelia was recently selected as one of the 100 Most Inspiring People in the life sciences sponsored by PharmaVoice.
Adrelia earned a Doctor of Pharmacy degree from the College of Pharmacy at Florida A&M University. She is a registered Pharmacist and a certified Project Management Professional.
Joel Berry
Stephen Theriault
Katherine Donovan
Katherine Donovan is a Lead Scientist in the Fischer Lab where she works on the development of molecular-glues and PROTAC molecules for targeted protein degradation. After joining the Fischer Lab as a Postdoc she developed an interest in proteomics as a specialized technology for quantifying protein-level expression changes in response to various perturbations. Katherine set up and led proteomics teams focused on degrader screening and target identification in the Fischer Lab as well as in the Center for Protein Degradation. She has used proteomics technology to identify the degradation targets of many molecules including the identification of SALL4 as the protein likely underlying the teratogenicity of thalidomide. Katherine led a large effort to map the degradable kinome and now to aid her quest to map the degradable proteome she has recently started a public degradation proteomics initiative which provides free target mapping of degraders.
Fia Navntoft
Kimberly Doggett
Martina Tyreus Hufnal
Martina is a principal in Fish & Richardson’s Delaware office. Her practice focuses on intellectual property litigation and covers a wide range of technologies. Martina has extensive experience in the pharmaceutical field, including Hatch-Waxman litigation, as well as chemical and software cases. Martina’s experience covers all aspects of pre-litigation diligence and litigation, including case assessment, electronic document collection and production, managing teams handling fact and expert discovery, settlement strategy, and trial work. She offers a diverse perspective to clients on litigation impact on business as well as implications of post-grant proceedings. Clients describe her as “outstanding lead counsel” who is “known for her prowess in post-grant proceedings and great in Hatch-Waxman actions.”
